Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Trial Combining TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

NCT01455389 is registered in ClinicalTrials.gov with Genprex, Inc. as lead sponsor.

NCT NCT01455389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01455389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Trial Combining TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Lead sponsor
Genprex, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
February 28, 2014
Completion date
September 28, 2020
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer